Myocardial Infarction

Type: Keyphrase
Name: Myocardial Infarction
First reported 10 hours ago - Updated 10 hours ago - 1 reports

Understanding factors that influence the use of risk scoring instruments in the management of ...

Cardiac risk scores estimate a patient's risk of future cardiac events or death. They are developed to inform treatment decisions of patients diagnosed with unstable angina or non-ST-elevation myocardial infarction.Despite recommending their use in guidelines ... [Published 7thSpace - 10 hours ago]
First reported 13 hours ago - Updated 13 hours ago - 1 reports

Mobile Health Applications in Cardiac Care

Cleland J, Barrett D. Future directions in cardiovascular care. European Cardiology 6(3), 30–32 (2010).* Concludes a strong clinical need to apply modern technologies in cardiovascular care and suggests clinical need is the key driver of using mobile ... [Published Diabetes Care - 13 hours ago]
First reported 14 hours ago - Updated 14 hours ago - 1 reports

Endothelial Progenitor Cells in AMI Patients With Diabetes

Harjai KJ, Stone GW, Boura J, Mattos L, Chandra H, Cox D, Grines L, O'Neill W, Grines C: Comparison of outcomes of diabetic and nondiabetic patients undergoing primary angioplasty for acute myocardial infarction. Am J Cardiol 2003, 91(9):1041–1045.Asahara ... [Published Theheart.org - 14 hours ago]
First reported 14 hours ago - Updated 14 hours ago - 1 reports

Cholesterol Guidelines Applied to HIV-infected Patients

Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Lloyd-Jones DM, Blum CB, et al . 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American ... [Published Theheart.org - 14 hours ago]
First reported Sep 21 2014 - Updated Sep 21 2014 - 1 reports

Counterintuitive Advice About Staying Alive After A Heart Attack

You don’t need to be a cardiologist to know that heart attacks kill lots of people. But unless you’re a cardiologist you may not know that many people remain at high risk for a second serious heart event in the first few months after a myocardial infarction ... [Published Austin American Statesman - Sep 21 2014]
First reported Sep 21 2014 - Updated Sep 21 2014 - 1 reports

Treatment of Heart Disease

The number 1 cause of death in developed countries is heart disease. It progresses slowly, without symptoms for many years, but when its presence is finally noted death or serious disability can result. Chest pain, especially persistent, recurrent and ... [Published BellaOnline - Sep 21 2014]
First reported Sep 20 2014 - Updated Sep 20 2014 - 1 reports

Apollo Hospitals Enterprise : Children's Hospital to launch Children's Weight Management Clinic

Obesity in Children is alarmingly increasing in India. Recent survey in Chennai shows 1 in 4 children in private schools were overweight/obese. Children who are overweight/obese develop medical problems like diabetes and hypertension at a very young age. ... [Published 4 Traders - Sep 20 2014]
First reported Sep 20 2014 - Updated Sep 20 2014 - 1 reports

Iran produces tPA

Iranian wins structural engineering fellowshipScience & Technology DeskMehdi Arezoumandi has won one of the 2014 O.H. Ammann Research Fellowship awards.The US Structural Engineering Institute’s (SEI) Technical Activities Division Executive Committee awarded ... [Published Iran Daily - Sep 20 2014]
First reported Sep 19 2014 - Updated Sep 19 2014 - 2 reports

Stentys announces positive results of Apposition III study

Stentys SA:Announces positive results of 1,000 patient Apposition III clinical study at two years after treatment of severe heart attack.At two years, MACE (defined as the composite of cardiac death, target-vessel myocardial infarction, emergent by-pass ... [Published Reuters UK - Sep 19 2014]
First reported Sep 16 2014 - Updated Sep 17 2014 - 3 reports

Intravascular ultrasound-guided intervention in patients with chronic total occlusion

A new study found that intravascular ultrasound (IVUS) -guided intervention in patients with chronic total occlusion (CTO) could improve outcomes compared to a conventional angiography-guided approach during percutaneous coronary intervention (PCI). The ... [Published Science Daily - Sep 17 2014]
First reported Sep 16 2014 - Updated Sep 17 2014 - 3 reports

STENTYS Stent Continues to Show Low Mortality Two Years after Treatment of a Heart Attack

Final 2 Year Results from APPOSITION III Study Presented Today at TCT Conference in Washington, D.CPRINCETON, N.J. & PARIS--(BUSINESS WIRE)--Regulatory News :STENTYS (Paris:STNT) (FR0010949404 — STNT), a medical technology company commercializing in Europe ... [Published Nasdaq - Sep 16 2014]
First reported Sep 16 2014 - Updated Sep 16 2014 - 2 reports

Re-Examination of the Antithrombotic Regimen in the STEMI-RADIAL Trial

In the STEMI-RADIAL (ST Elevation Myocardial Infarction treated by RADIAL or femoral approach) trial (1) , the primary endpoint of the cumulative incidence of major bleeding and vascular access site complications at 30 days was lower with transradial ... [Published Journal of the American College of Cardiology - Sep 16 2014]

Quotes

...Elizabeth Selvin, associate professorprofessor of epidemiology at Johns Hopkins University. "Statin treatment may not be sufficient to prevent damage to the heart in people with diabetes. Even though there may be no symptoms yet, our research suggests there is microvascular damage being done to the heart which is leading to heartheart failure and even death. It puts what we know about heart damage in diabetes on its head. It looks like diabetes may be slowly killing heart muscle in ways we had not thought of before."
"We are excited about the future prospects for CVRx and Barostim Therapy.  Our confidence is based on continued revenue growth in Europe for the resistant hypertension indication as well as the speed with which CVRx was able to complete enrollment of their randomized heart failure study in Europe , Canada , and the United States " said Jay McNeil , Managing Director within Silicon Valley Bank's national lifelife sciences practice
d'Emden MC, et al "Favorable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study" Diabetologia 2014; DOI: 10.1007/s00125-014-3344-3
...ischemic events,” said lead investigator Nikolaus Sarafoff, M D , from Deutsches Herzzentrum and Klinikum der Universität, both in Munich, Germany. "These results suggest that physicians should weigh the trade-off between ischemic and bleeding risk when choosing the shorter or longer duration of triple therapy."

More Content

All (765) | News (638) | Reports (0) | Blogs (121) | Audio/Video (0) | Fact Sheets (1) | Press Releases (1)
sort by: Date | Relevance
New Study Examines the Optimal Duration Time of... [Published Diagnostic & Invasive Cardiology - 2 hours ago]
Research Findings Demonstrate miRagen Therapeut... [Published BioSpace - 5 hours ago]
Healthline’s New HealthData Engine Turns Unstru... [Published PRWeb - 5 hours ago]
Healthlines New HealthData Engine Turns Unstruc... [Published KWQC - 5 hours ago]
Elevated Blood Sugar a Cardiovascular Disease R... [Published Lab Medica - 9 hours ago]
Understanding factors that influence the use of... [Published 7thSpace - 10 hours ago]
CVRx® Secures $15 Million Growth Capital Facili... [Published RCL Advisors - 10 hours ago]
Mobile Health Applications in Cardiac Care [Published Diabetes Care - 13 hours ago]
Varenicline and Cardiovascular Adverse Events [Published General Medicine eJournal - 13 hours ago]
Cholesterol Guidelines Applied to HIV-infected ... [Published Theheart.org - 14 hours ago]
Endothelial Progenitor Cells in AMI Patients Wi... [Published Theheart.org - 14 hours ago]
Counterintuitive Advice About Staying Alive Aft... [Published Austin American Statesman - Sep 21 2014]
Counterintuitive Advice About Staying Alive Aft... [Published Forbes.com - Sep 21 2014]
Fibrates Can Reduce Cardiovascular Risk in Type... [Published Diabetes in Control - Sep 21 2014]
Treatment of Heart Disease [Published BellaOnline - Sep 21 2014]
Curcumin inhibits EMMPRIN and MMP-9 expression ... [Published 7thSpace - Sep 21 2014]
Apollo Hospitals Enterprise : Children's Hospit... [Published 4 Traders - Sep 20 2014]
HIF-1α Signaling Activation by Post-Ischemia Tr... [Published Plosone.org - Sep 20 2014]
Follow-up of Blood-Pressure Lowering and Glucos... [Published New England Journal of Medicine - Sep 20 2014]
Effect lifestyle changes to reduce heart attack... [Published Khaleej Times - Sep 20 2014]
Iran produces tPA [Published Iran Daily - Sep 20 2014]
Erythropoietin Protects Cardiomyocytes from Cel... [Published Plosone.org - Sep 19 2014]
miRNA signature of unfolded protein response in... [Published 7thSpace - Sep 19 2014]
Study Evaluates Triple Therapy for Anticoagulat... [Published Diagnostic & Invasive Cardiology - Sep 19 2014]
New Study Finds Systemic Hypothermia Does Not I... [Published Diagnostic & Invasive Cardiology - Sep 19 2014]
NeoStem: Timing Is Everything [Published Seeking Alpha - Sep 19 2014]
Recombinant Therapeutic Proteins Market & Pipel... [Published Global Information Inc - Sep 19 2014]
On The Pulse - 19th September 2014 [Published OnMedicanet - Sep 19 2014]
Stentys announces positive results of Appositio... [Published Reuters UK - Sep 19 2014]
Stentys : Stent Updates on Apposition III [Published 4 Traders - Sep 19 2014]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
STENTYS Stent Continues to Show Low Mortality T... [Published EON Science - Sep 16 2014]
PRINCETON, N.J. & PARIS--(EON: Enhanced Online News)--Regulatory News : STENTYS (Paris:STNT) (FR0010949404 — STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing® stent to treat acute myocardial infarction ...
STENTYS Stent Continues to Show Low Mortality T... [Published Business Wire Science: Science News - Sep 16 2014]
PRINCETON, N.J. & PARIS--(BUSINESS WIRE)--Regulatory News : STENTYS (Paris:STNT) (FR0010949404 — STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing® stent to treat acute myocardial infarction (AMI), ...
STENTYS Stent Continues to Show Low Mortality T... [Published Business Wire Health News - Sep 16 2014]
PRINCETON, N.J. & PARIS--(BUSINESS WIRE)--Regulatory News : STENTYS (Paris:STNT) (FR0010949404 — STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing® stent to treat acute myocardial infarction (AMI), ...
CellProThera® and BioCardia® Partner on Phase I... [Published Business Wire Health News - Sep 15 2014]
MULHOUSE, France & SAN CARLOS, Calif.--(BUSINESS WIRE)--CellProThera and BioCardia partner in Phase II EXCELLENT Trial studying blood stem cell therapy for acute myocardial infarction delivered via the Helix transendocardial delivery system ...
Research and Markets: Global Myocardial Infarct... [Published Business Wire Professional Services News - Sep 11 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/3nwtz6/myocardial) has announced the addition of the "Myocardial Infarction - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
Akers Biosciences Signs Feasibility Study Deal ... [Published GlobeNewswire: Acquisitions News - Jul 28 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.